Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Natera's Signatera Genome assay was featured in the ESMO Presidential Symposium presentation of the phase III VOLGA trial in muscle-invasive bladder cancer, part of 25 ESMO abstracts including 9 oral presentations. VOLGA showed Signatera ctDNA dynamics were highly predictive of event-free survival: 24-month EFS was 91% for persistently ctDNA-negative patients versus 55% for those who stayed positive.
Key figures
- Drug Name
- Signatera Genome with Phased and Structural Variants
- Phase Of Trial
- Phase 3
- Esmo abstracts
- 25
- Oral presentations
- 9
- Volga 24mo efs ctdna cleared
- 81%
- Volga 24mo efs persistent negative
- 91%
- Volga 24mo efs persistent positive
- 55%
- Nsclc ctdna detection pre treatment
- 99%
- Nsclc clearance p CR predictive value
- 83%
- Her2 breast maintained mrd negativity
- 81%
- Endometrial NPV disease specific events
- 97%
- Endometrial signatera positive post surgery
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.